Comparative study reveals distinct survival outcomes based on residual disease in triple-negative breast cancer, highlighting early recurrence risks.
Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival. However, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with non-TNBC, particularly in the first 3 years.
No takes yet. Share an insight, caveat, or question.
Liedtke et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: